Litcius/Paper detail

Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

Carolina Porras, Sabrina H. Tsang, Rolando Herrero, Diego Guillén, Teresa M. Darragh, Mark H. Stoler, Allan Hildesheim, Sarah Wagner, Joseph F. Boland, Douglas R. Lowy, John T. Schiller, Mark Schiffman, John Schussler, Mitchell H. Gail, Wim Quint, Rebeca Ocampo, Jorge Morales, Ana Cecilia Rodríguez, Shangying Hu, Joshua N. Sampson, Aimée R. Kreimer, Bernal Cortés, Paula González, Rolando Herrero, Silvia E. Jiménez, Carolina Porras, Ana Cecilia Rodríguez, Allan Hildesheim, Aimée R. Kreimer, Douglas R. Lowy, Mark Schiffman, John T. Schiller, Mark E. Sherman, Lígia A. Pinto, Troy J. Kemp, Mary Sidawy, Wim Quint, Leen‐Jan van Doorn, Linda Struijk, Joel M. Palefsky, Teresa M. Darragh, Mark H. Stoler

2020The Lancet Oncology130 citationsDOIOpen Access PDF

Topics & Concepts

Bivalent (engine)MedicineVaccine efficacyVirologyVaccinationChemistryOrganic chemistryMetalCervical Cancer and HPV ResearchHead and Neck Cancer StudiesEndometrial and Cervical Cancer Treatments
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial | Litcius